‘PET score’ Tops Neuropsych Testing in Tracking Alzheimer’s Progression
Positron emission tomography (PET) scans using F-18 florbetaben (18F-FDG) are more reliable than traditional neuropsychological testing in tracking the evolution of mild cognitive impairment to Alzheimer’s disease, researchers reported in the Journal of Nuclear Medicine.
Positron emission tomography (PET) scans using F-18 florbetaben (18F-FDG) are more reliable than traditional neuropsychological testing in tracking the evolution of mild cognitive impairment to Alzheimer’s disease, researchers reported in the Journal of Nuclear Medicine.
A University of Manchester, U.K., team led by Karl Herholz developed a “PET score” based on scans of 94 patients with mild cognitive impairment (MCI), 40 patients with Alzheimer’s disease, and 44 controls. The subjects, part of the Alzheimer Disease Neuroimaging Initiative (ADNI), received four scans and clinical assessments over two years.
PET scores provided far higher test-retest reliability than standard neuropsychological scores done with the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-cog) and Mini-Mental State Examination. The scores also provided better measurements of progression, Herholz and colleagues found.
At the same time, FDG-PET scans relate directly to ADAS-cog scores, thus providing a valid measure of cognitive impairment. In addition, PET scores of patients who had mild cognitive impairment at the beginning of the study predicted clinical progression to dementia with a higher accuracy than Mini-Mental State Examination and ADAS-cog, the researchers reported.
FDG-PET provides insights into the impairment of synaptic function and could, with appropriate standardization, qualify as a biomarker, the researchers said.
"Prevention of dementia by drugs applied at MCI stage would greatly improve quality of life for patients and reduce costs of dementia care and treatment," Herholz and colleagues wrote.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
